DC Chemicals Limited
China
Product Name: Tiludronate disodium hemihydrate
Price: $Inquiry/100mg $Inquiry/250mg $Inquiry/1g
Purity: 98.0%
Stocking Period: 3 Day
Contact: Tony Cao

155453-10-4

155453-10-4 structure

Name: Tiludronate disodium hemihydrate
Chemical Name: tetrasodium,[(4-chlorophenyl)sulfanyl-[hydroxy(oxido)phosphoryl]methyl]-hydroxyphosphinate,hydrate
CAS Number: 155453-10-4
Molecular Formula: C₁₄H₁₆Cl₂Na₄O₁₃P₄S₂
Molecular Weight: 743.15900
Catalog: Signaling Pathways Membrane Transporter/Ion Channel Proton Pump
Create Date: 2018-07-06 14:22:11
Modify Date: 2024-01-13 19:39:06
Tiludronate (Tiludronic Acid) disodium hemihydrate, an orally active bisphosphonate, can act an osteoregulator. Tiludronate disodium hemihydrate is used for the research of the metabolic bone disorders. Tiludronate disodium hemihydrate is a potent inhibitor of the osteoclast vacuolar H+-ATPase. Antiresorptive and anti-inflammatory properties[1][2][3][4].

Name	tetrasodium,[(4-chlorophenyl)sulfanyl-[hydroxy(oxido)phosphoryl]methyl]-hydroxyphosphinate,hydrate
Synonyms	Phosphonic acid,(((4-chlorophenyl)thio)methylene)bis-,disodium salt,hydrate (2:1) UNII-39SMX0W5WK P,P'-(((4-Chlorophenyl)thio)methylene)bisphosphonic acid,disodium hemihydrate Tiludronic acid disodium salt hemihydrate [MI] Tiludronate disodium hemihydrate

Description	Tiludronate (Tiludronic Acid) disodium hemihydrate, an orally active bisphosphonate, can act an osteoregulator. Tiludronate disodium hemihydrate is used for the research of the metabolic bone disorders. Tiludronate disodium hemihydrate is a potent inhibitor of the osteoclast vacuolar H+-ATPase. Antiresorptive and anti-inflammatory properties[1][2][3][4].
Related Catalog	Research Areas >> Metabolic Disease Signaling Pathways >> Membrane Transporter/Ion Channel >> Proton Pump
In Vitro	The ability of Tiludronate to inhibit proton transport is 5-fold higher in kidney-derived vesicles (IC50=1.1 mM) and 10,000-fold higher in vesicles derived from osteoclasts (IC50=466 nM). Tiludronate also potently inhibited proton transport in yeast microsomal preparations (IC50=3.5 microM) and inhibited the activity of purified yeast V-ATPase. The inhibition of the osteoclast V-ATPase-mediated proton transport by Tiludronate is rapid, pH-dependent, and reversible[3].
In Vivo	Tiludronate exerts a dose-dependent inhibitory activity on bone resorption. Tiludronate could act on mature osteoclasts by reducing their capacity to secrete proton into the resorption space and also by favoring their detachment from the bone matrix. Tiludronate is also tested in other models of osteoporosis. In the castrated male rat model, Tiludronate (5-200 mg/kg; p.o.) prevents the decrease in the skeletal mass, assessed physically by measuring the bone weight and density or chemically by determining the calcium and phosphate content[3].
References	[1]. Reginster JY, et al. Prevention of postmenopausal bone loss by tiludronate. Lancet. 1989;2(8678-8679):1469-1471. [2]. Nunes NLT, et al. Effects of local administration of tiludronic acid on experimental periodontitis in diabetic rats. J Periodontol. 2018;89(1):105-116. [3]. Bonjour JP, et al. Tiludronate: bone pharmacology and safety. Bone. 1995;17(5 Suppl):473S-477S. [4]. David P, et al. The bisphosphonate tiludronate is a potent inhibitor of the osteoclast vacuolar H(+)-ATPase. J Bone Miner Res. 1996;11(10):1498-1507.

Molecular Formula	C₁₄H₁₆Cl₂Na₄O₁₃P₄S₂
Molecular Weight	743.15900
Exact Mass	741.79500
PSA	340.51000
LogP	5.83070

155453-10-4	149845-07-8
35035-05-3	54394-90-0
479347-85-8	73530-15-1
6054-98-4	63528-82-5
60908-54-5	53778-50-0